Abstract

BackgroundAnti TNF-alpha drugs have revolutionized the management of immune-mediated inflammatory diseases (IMIDs). Since 2015, several biosimilar products have been marketed and reimbursed after the expiry of the originator patents of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Biosimilar low molecular weight heparin products.
E Gray ... B Mulloy
Journal of thrombosis and haemostasis : JTH | VOL. 7
E Gray, et. al.E Gray ... B Mulloy
24 Apr 2009
Effect on Patients’ Outcomes of a Change to Biosimilar Filgrastim Product in Autologous Stem Cell Mobilization
Neeta Shirvaikar ... Melissa Jenkins
The Canadian journal of hospital pharmacy | VOL. 74
Neeta Shirvaikar, et. al.Neeta Shirvaikar ... Melissa Jenkins
19 Apr 2021
SP0038 How Can The Proliferation of Biosimilars Impact on R&D and Quality?
R Van Vollenhoven
Annals of the Rheumatic Diseases | VOL. 75
R Van VollenhovenR Van Vollenhoven
01 Jun 2016
Biosimilars approved for treatment of inflammatory rheumatological diseases.
Stephen M Mahler ... Andri Wardiana
International journal of rheumatic diseases | VOL. 19
Stephen M Mahler, et. al.Stephen M Mahler ... Andri Wardiana
01 Nov 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers